AIM ImmunoTech (NYSE:AIM) released its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02), Fidelity Earnings reports. AIM ImmunoTech had a negative net margin of 6,823.39% and a negative return on equity of 30.48%.
NYSE AIM traded up $0.12 during trading hours on Thursday, hitting $2.39. The company had a trading volume of 25,966 shares, compared to its average volume of 3,042,122. The company has a debt-to-equity ratio of 0.03, a quick ratio of 50.01 and a current ratio of 50.01. AIM ImmunoTech has a 1-year low of $1.60 and a 1-year high of $4.30. The business has a 50 day moving average of $2.37 and a 200-day moving average of $2.12.
Separately, Maxim Group restated a “buy” rating and issued a $2.00 price objective on shares of AIM ImmunoTech in a research note on Tuesday, February 9th.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome.
Featured Article: What is the significance of the death cross?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.